Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Brigette Ma, MD
Temporarily Closed to Accrual
September 8, 2020
Most Recent Amendment Date:
February 16, 2021
Head and Neck [HN]
Head and Neck
To determine if adding nivolumabto platinum-gemcitabine as first-line treatment improves overall survival (OS)for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC).
Pathologically (histologically or cytologically) proven diagnosis of NPC that has recurred at locoregional and/or distant sites prior to registration. For locoregional recurrence, the disease must not be amenable to potentially curative surgery or re-irradiation. The following histological types are accepted: (a) Keratinizing – squamous cell carcinoma; (b) Non-keratinizing – undifferentiated or poorly differentiated.
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.